This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Commissariat a L'energie Atomique Et Aux Energies Alternatives, National Institute of Health and Medical Research. Active years: 2018-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 5,383 
2 out of 8,845 
2 out of 1,853 
Years Active: 2018-2021
Title: The Innovations of Philippe Hantraye
Introduction
Philippe Hantraye is a notable inventor based in France. He has made significant contributions to the field of biomarker research, particularly in relation to peripheral benzodiazepine receptors. His work has implications for both normal and pathological conditions, showcasing the importance of innovative approaches in medical diagnostics.
Latest Patents
Philippe Hantraye holds a patent titled "Use Of 7-Chloro-N,n,5-Trimethyl-4-Oxo-3-Phenyl-3,5-Dihydro-4h-Pyridazino[4,5-B]indole-1-Acetamide As A Biomarker Of Peripheral Benzodiazepine Receptor Levels." This patent describes the use of a radiolabelled form of the compound as a biomarker for detecting PBR levels in individuals. The method outlined in the patent is crucial for diagnosing conditions associated with these receptor levels.
Career Highlights
Throughout his career, Philippe has worked with prominent companies such as Sanofi-Aventis and Commissariat à l'Énergie Atomique (CEA). His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of medical research.
Collaborations
Philippe has collaborated with notable colleagues, including Jesus Benavides and Herve Boutin. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Philippe Hantraye's work exemplifies the intersection of innovation and medical science. His contributions to biomarker research are significant and continue to influence the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile